| scholarly article | Q13442814 |
| P356 | DOI | 10.1074/JBC.M403968200 |
| P698 | PubMed publication ID | 15145935 |
| P50 | author | Iqbal S Grewal | Q100761370 |
| P2093 | author name string | Hua Wang | |
| Wyne P Lee | |||
| Jed Ross | |||
| Dhaya Seshasayee | |||
| Richard Carano | |||
| Peter Gribling | |||
| Nicholas Van Bruggen | |||
| P2860 | cites work | CD40 AND CD154 IN CELL-MEDIATED IMMUNITY | Q22255634 |
| Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 | ||
| TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells | Q24315251 | ||
| A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 | ||
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 | ||
| The TNF and TNF receptor superfamilies: integrating mammalian biology | Q28203717 | ||
| OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
| CD40 signaling of monocyte inflammatory cytokine synthesis through an ERK1/2-dependent pathway. A target of interleukin (il)-4 and il-10 anti-inflammatory action | Q28609312 | ||
| Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand | Q29619331 | ||
| Mitogen-activated protein kinases: specific messages from ubiquitous messengers | Q30303652 | ||
| Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs | Q32015794 | ||
| Osteoprotegerin ligand: a common link between osteoclastogenesis, lymph node formation and lymphocyte development. | Q33611312 | ||
| Development and maturation of secondary lymphoid tissues. | Q33652498 | ||
| The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. | Q33823576 | ||
| Apoptosis in human autoimmune diseases | Q33836352 | ||
| Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression | Q33944735 | ||
| Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. | Q34469691 | ||
| TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor | Q36380989 | ||
| RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism | Q37108966 | ||
| Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin | Q37629829 | ||
| RANKing the importance of measles virus in Paget's disease | Q40326890 | ||
| The many roles of CD40 in cell-mediated inflammatory responses | Q41203088 | ||
| The proto-oncogene Bcl-2 and its role in regulating apoptosis | Q41492030 | ||
| T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ | Q59064307 | ||
| P433 | issue | 29 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | inflammation | Q101991 |
| P1104 | number of pages | 8 | |
| P304 | page(s) | 30202-30209 | |
| P577 | publication date | 2004-05-15 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response | |
| P478 | volume | 279 |
| Q36493751 | Anti-RANKL treatment inhibits erosive joint destruction and lowers inflammation but has no effect on bone formation in the delayed-type hypersensitivity arthritis (DTHA) model |
| Q36928773 | Association analyses suggest the effects of RANK and RANKL on age at menarche in Chinese women. |
| Q39002838 | Cell Signaling Pathways That Regulate Antigen Presentation |
| Q60300559 | Cigarette smoke-induced RANKL expression enhances MMP-9 production by alveolar macrophages |
| Q37767159 | Do RANKL inhibitors (denosumab) affect inflammation and immunity? |
| Q37441693 | Effects of RANKL-Targeted Therapy in Immunity and Cancer |
| Q48261321 | ICOS-Ligand Triggering Impairs Osteoclast Differentiation and Function In Vitro and In Vivo |
| Q59356917 | Interferon-Gamma-Mediated Osteoimmunology |
| Q39129914 | Macrophages and skeletal health |
| Q36324916 | Osteoclast precursors, RANKL/RANK, and immunology |
| Q37945476 | Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. |
| Q90288380 | Prolonged exposure to simulated microgravity diminishes dendritic cell immunogenicity |
| Q37738754 | RANK ligand: effects of inhibition. |
| Q37727115 | RANKL enhances macrophage paracrine pro-calcific activity in high phosphate-treated smooth muscle cells: dependence on IL-6 and TNF-α. |
| Q47133428 | RANKL-mediated harmonious dialogue between fetus and mother guarantees smooth gestation by inducing decidual M2 macrophage polarization |
| Q34993353 | Runx2-upregulated receptor activator of nuclear factor κB ligand in calcifying smooth muscle cells promotes migration and osteoclastic differentiation of macrophages. |
| Q35689812 | Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis |
| Q36591727 | TGF-beta1 on osteoimmunology and the bone component cells |
| Q35083231 | The roles of lipid oxidation products and receptor activator of nuclear factor-κB signaling in atherosclerotic calcification |
| Q39996337 | Transcriptional regulation of human RANK ligand gene expression by E2F1. |
| Q86025548 | Zoledronate but not denosumab suppresses macrophagic differentiation of THP-1 cells. An aetiologic model of bisphosphonate-related osteonecrosis of the jaw (BRONJ) |
Search more.